5.13
-0.61 (-10.55%)
| Previous Close | 5.74 |
| Open | 5.35 |
| Volume | 236,946 |
| Avg. Volume (3M) | 2,413,388 |
| Market Cap | 7,658,372 |
| Price / Sales | 1.22 |
| Price / Book | 1.54 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Profit Margin | -43.80% |
| Operating Margin (TTM) | -42.26% |
| Diluted EPS (TTM) | -1.23 |
| Quarterly Revenue Growth (YOY) | 77.50% |
| Total Debt/Equity (MRQ) | 88.08% |
| Current Ratio (MRQ) | 1.55 |
| Operating Cash Flow (TTM) | -3.88 M |
| Levered Free Cash Flow (TTM) | -2.26 M |
| Return on Assets (TTM) | -21.70% |
| Return on Equity (TTM) | -108.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Evoke Pharma, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.34% |
| % Held by Institutions | 16.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bleichroeder Lp | 31 Mar 2025 | 68,750 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jul 2025 | Announcement | Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 |
| 13 May 2025 | Announcement | Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update |
| 28 Apr 2025 | Announcement | Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |